Articles

DAPA-HF trial: dapagliflozin evolves from a glucose-lowering agent to a therapy for heart failure

Edgardo Kaplinsky MD

Article Type

Review

Published

This review describes the results of the DAPA-HF (Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure) trial and the recently published Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction (DEFINE-HF) trial. In addition, the thought-to-be mechanisms of action of SGLT2 inhibitors beyond their known glucose-lowering effects.

Read more

Tumor lysis syndrome in childhood malignancies

Wing Lum Cheung MBBS, MRCPCH, Kam Lun Hon MBBS, MD (CUHK), FAAP, FCCM, Cheuk Man Fung MBChB, MRCPCH, Alexander KC Leung MBBS, FRCPC, FRCP (UK & Irel), FRCPCH, FAAP

Article Type

Review

Published

This review provides an update on the current understanding, evaluation, and management of tumor lysis syndrome in childhood malignancies.

Read more

Considerations for the US health-system pharmacist in a world of biosimilars

Andrea Zlatkus CRHC, Todd Bixby RPh, Kavitha Goyal MD

Article Type

Editorial

Published

This editorial article provides an overview of the evolving healthcare landscape shaped by the entry of multiple biosimilars, including for a given reference product, and their impact on the healthsystem pharmacist with respect to formulary assessment, implementation, and education of various health-system stakeholders, including patients.

Read more

Register for alerts

I would like to be contacted by Drugs in Context when new articles are posted.